Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced the appointment of
Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has
more than 20 years of biotechnology research, development, and
commercialization experience.
“It is a pleasure to welcome Sunil to our Board of Directors,”
said Jill C. Milne, Ph.D., Chief Executive Officer at Astria
Therapeutics. “His extensive drug development and clinical
expertise strongly complements our Board’s skills and experiences,
and we look forward to his contributions as we continue to advance
our programs into later-stage clinical development with the goal of
STAR-0215 becoming the market leader in hereditary angioedema.”
“I am excited to join the Board at Astria at this important
stage as the organization prepares for Phase 3 development of
STAR-0215,” said Dr. Agarwal. “STAR-0215 has the potential to
significantly improve the lives of patients and I look forward to
contributing to its progress at this exciting time.”
Dr. Agarwal currently serves on the Board of Directors of
Arvinas and was previously a Board member of Calithera Biosciences,
MyoKardia, and Vitrisa Therapeutics. Throughout his career, Dr.
Agarwal has served in leadership and executive roles in the
biopharmaceutical industry. He most recently served as Executive
Vice President and Chief Development Officer for Sana Biotechnology
and, prior to that, as President of Research and Development at
Juno Therapeutics until its acquisition by Celgene. At Ultragenyx
he served as Executive Vice President and Chief Medical Officer and
at Genentech as Senior Vice President and Global Development Head.
He has led global approvals across multiple indications for
Rituxan, Actemra, Xolair, Lucentis, Ocrevus, Mepsevii, Breyanzi,
and Gliadel. Dr. Agarwal holds a B.S. in neurobiology from Cornell
University and earned his M.D. from Tufts University School of
Medicine. He completed his residency at Children’s National Medical
Center (CNMC), Washington, D.C., and practiced in the CNMC
Pediatric Emergency Department.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of applicable securities laws and regulations
including, but not limited to, statements regarding: progressing
our programs into later stage clinical development; the potential
of STAR-0215 becoming a market leader in hereditary angioedema
(HAE) and its potential to improve the lives of HAE patients; and
our corporate strategy and vision, including our goal to bring
life-changing therapies to patients and families affected by
allergic and immunological diseases. The use of words such as, but
not limited to, “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would,” or "vision," and similar words expressions are intended to
identify forward-looking statements. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on Astria’s current beliefs, expectations
and assumptions regarding the future of its business, future plans
and strategies, future financial performance, results of
pre-clinical and clinical results of the Astria’s product
candidates and other future conditions. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including risks and
uncertainties related to: changes in applicable laws or
regulations; the possibility that we may be adversely affected by
other economic, business, and/or competitive factors; risks
inherent in pharmaceutical research and development, such as:
adverse results in our drug discovery, preclinical and clinical
development activities, the risk that the results of preclinical
studies may not be replicated in clinical trials, that the
preliminary, initial or interim results from clinical trials may
not be indicative of the final results, that the results of early
stage clinical trials, such as the initial results from the
ALPHA-STAR Phase 1b/2 clinical trial, may not be replicated in
later stage clinical trials, the risk that we may not be able to
enroll sufficient patients in our clinical trials on a timely
basis, and the risk that any of our clinical trials may not
commence, continue or be completed on time, or at all; decisions
made by, and feedback received from, the U.S. Food and Drug
Administration and other regulatory authorities on our regulatory
and clinical trial submissions and other feedback from potential
clinical trial sites, including investigational review boards at
such sites, and other review bodies with respect to STAR-0215,
STAR-0310, and any other future development candidates; our ability
to manufacture sufficient quantities of drug substance and drug
product for STAR-0215, STAR-0310, and any other future product
candidates on a cost-effective and timely basis, and to develop
dosages and formulations for STAR-0215, STAR-0310, and any other
future product candidates that are patient-friendly and
competitive; our ability to develop biomarker and other assays,
along with the testing protocols therefor; our ability to obtain,
maintain and enforce intellectual property rights for STAR-0215,
STAR-0310 and any other future product candidates; our potential
dependence on collaboration partners; competition with respect to
STAR-0215, STAR-0310, or any of our other future product
candidates; the risk that survey results, modeling data and market
research may not be accurate predictors of the commercial landscape
for HAE, the ability of STAR-0215 to compete in HAE and the
anticipated position and attributes of STAR-0215 in HAE based on
clinical data to date, its preclinical profile, pharmacokinetic
modeling, market research and other data; risks that any of our
clinical trials of STAR-0310 may not commence, continue or be
completed on time, or at all; risks that results of preclinical
studies of STAR-0310 will not be replicated in clinical trials; our
ability to manage our cash usage and the possibility of unexpected
cash expenditures; our ability to obtain necessary financing to
conduct our planned activities and to manage unplanned cash
requirements; the risks and uncertainties related to our ability to
recognize the benefits of any additional acquisitions, licenses or
similar transactions; and general economic and market conditions;
as well as the risks and uncertainties discussed in the “Risk
Factors” section of our Annual Report on Form 10-K for the period
ended December 31, 2023 and in other filings that we may make with
the Securities and Exchange Commission. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Astria may not actually achieve the
forecasts or expectations disclosed in our forward-looking
statements, and investors and potential investors should not place
undue reliance on Astria’s forward-looking statements. Neither
Astria, nor its affiliates, advisors or representatives, undertake
any obligation to publicly update or revise any forward-looking
statement, whether as result of new information, future events or
otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing Astria’s views
as of any date subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409245984/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Gen 2024 a Gen 2025
